oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Atypic hand and foot syndrome due to capecitabine therapy: a case report
Eylem KARATAY,Erdem AKBAL,Dicle KOCA,Gülsüm G?NüLALAN
Turkish Journal of Oncology , 2008,
Abstract: Hand-foot syndrome, also known as palmar-plantar dysesthesia, is a drug reaction characterized by dysesthesia, erythema, and edema desquamation in the palms of the hands and soles of the feet. Cytarabine, docetaxel, ARA-C, capecitabine and 5-FU are the drugs related with hand-foot syndrome. In our case, erythema and edema desquamation developed on the dorsal area of the hand and wrist after capecitabine treatment. The lesion is reported because its location is rare and it has not been reported before.
An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?  [cached]
Vasudevan Biju
Indian Journal of Pharmacology , 2010,
Abstract: A 59-year-old man with adenocarcinoma of stomach was prescribed capecitabine as adjuvant chemotherapy. After two cycles of therapy, patient developed hyperpigmentation on hands and feet. Examination revealed a peculiar distribution of hyperpigmentation on hands and feet and in addition, hyperpigmented spots on the dorsum of tongue. Although hand-foot syndrome (HFS) to capecitabine solely manifesting as palmoplantar hyperpigmentation has been described earlier, this is probably the first instance wherein oral pigmentation has also been found in association. In addition, this finding lends support to the growing argument of hyperpigmentation being a separate entity: different from HFS, both therefore being separate adverse effects of the same drug.
Hand-Foot Syndrome Accompanied by Severe Oral Lesions during Capecitabine Therapy for Metastatic Colon Carcinoma
Zehra A?iran SERDAR,I??k G?NEN?,?irin YA?AR,Tu?ba DORUK
Marmara Medical Journal , 2011,
Abstract: Hand-foot syndrome (HFS) is a side effect of some chemotherapeutics appearing as dysesthesia, sharp-edged plaques and symmetrical lesions on palmoplantar areas. Our case is a 68-year-old male patient who developed a slight erythema and desquamation on the palms and soles of the feet during the third cycle of capecitabine treatment for advanced metastatic carcinoma. With this case report we aimed to draw attention to the development of HFS in patients receiving chemotherapy with capecitabine and raise awareness in the issue. The nonexistance of data in contemporary literature about the occurrence of hemorrhagic bullae in the oral mucosa makes our case noteworthy. (Marmara Medical Journal 2011;24:198-200)
Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin  [PDF]
Yulia Kundel, Nicola J. Nasser, Ofer Purim, Rinat Yerushalmi, Eyal Fenig, Raphael M. Pfeffer, Salomon M. Stemmer, Shulamith Rizel, Zvi Symon, Bella Kaufman, Aaron Sulkes, Baruch Brenner
PLOS ONE , 2013, DOI: 10.1371/journal.pone.0068327
Abstract: Background Pain from bone metastases of breast cancer origin is treated with localized radiation. Modulating doses and schedules has shown little efficacy in improving results. Given the synergistic therapeutic effect reported for combined systemic chemotherapy with local radiation in anal, rectal, and head and neck malignancies, we sought to evaluate the tolerability and efficacy of combined capecitabine and radiation for palliation of pain due to bone metastases from breast cancer. Methodology/Principal Findings Twenty-nine women with painful bone metastases from breast cancer were treated with external beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks. Oral capecitabine 700 mg/m2 twice daily was administered throughout radiation therapy. Rates of complete response, defined as a score of 0 on a 10-point pain scale and no increase in analgesic consumption, were 14% at 1 week, 38% at 2 weeks, 52% at 4 weeks, 52% at 8 weeks, and 48% at 12 weeks. Corresponding rates of partial response, defined as a reduction of at least 2 points in pain score without an increase in analgesics consumption, were 31%, 38%, 28%, 34% and 38%. The overall response rate (complete and partial) at 12 weeks was 86%. Side effects were of mild intensity (grade I or II) and included nausea (38% of patients), weakness (24%), diarrhea (24%), mucositis (10%), and hand and foot syndrome (7%). Conclusions/Significance External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin. The overall and complete response rates in our study are unusually high compared to those reported for radiation alone. Further evaluation of this approach, in a randomized study, is warranted. Trial Registration ClinicalTrials.gov NCT01784393NCT01784393
Síndrome m o-pé induzida por quimioterapia: relato de um caso Síndrome mano-pie inducida por quimioterapia: relato de un caso Hand-foot syndrome induced by chemotherapy: a case study  [cached]
Delma Aurélia da Silva Sim?o,Elenice Dias Ribeiro de Paula Lima,Raíssa Silva de Souza,Tiago Vitervo Faria
Revista Brasileira de Enfermagem , 2012, DOI: 10.1590/s0034-71672012000200026
Abstract: Objetivou-se relatar um caso de uma paciente que apresentou síndrome m o-pé de grau 3, decorrente do uso do quimioterápico Capecitabina e para a qual foi utilizada massagem local com creme hidratante aquoso à base de aloe vera. A capacidade funcional da paciente foi avaliada utilizando-se a Escala de Performance ECOG e as les es fotografadas durante as consultas de enfermagem que ocorreram em intervalos de dez dias, totalizando quarenta dias de acompanhamento. Observou-se melhora significativa da integridade tissular, com regress o total dos sintomas, importante ganho em qualidade de vida, e retorno imediato ao tratamento quimioterápico. Acredita-se que o aloe vera pode ser um importante coadjuvante na assistência de enfermagem a pacientes submetidos à quimioterapia antineoplásica. El estudio tiene como objetivo presentar un caso de una paciente que desarrolló la Síndrome Pie-Mano de grado 3 debido al uso de capecitabina y en que se utilizó el masaje con crema hidratante aloe vera, en base acuosa. La capacidad funcional de la paciente se evaluó mediante la Escala de Desempe o ECOG y las lesiones fueran fotografiadas durante las consultas de enfermería que ocurrirán a intervalos de diece días, con un total de cuarenta días de seguimiento. Hubo una mejora significativa en la integridad de los tejidos, con la regresión total de los síntomas, un aumento importante en la calidad de vida, y el retorno inmediato a la quimioterapia. Se cree que el aloe vera puede ser un componente importante en los cuidados de enfermería en pacientes sometidos a quimioterapia contra el cáncer. The study was aimed at reporting a case of a patient who developed Hand-Foot Syndrome (HFS) grade 3 due the use of capecitabine and for which massage was used with aqueous-based moisturizer, aloe vera. The patient's functional capacity was assessed using the ECOG Performance Scale and the lesions were photographed during nursing appointment that occurred at intervals of ten days, totaling forty days of monitoring. There was significant improvement in tissue integrity, with total regression of symptoms, an important gain in quality of life, and immediate return to chemotherapy. It is believed that aloe vera can be an important component in nursing care in patients undergoing cancer chemotherapy.
Efficacy and Toxicity of Metronomic Capecitabine in Advanced Hepatocellular Carcinoma  [PDF]
Ashraf Farrag
Journal of Cancer Therapy (JCT) , 2012, DOI: 10.4236/jct.2012.31010
Abstract: Background: Hepatocellular carcinoma (HCC) is a hypervascular tumor. Metronomic chemotherapy; the continuous administration of low-dose chemotherapy; has both cytotoxic and antiangiogenic effects with low toxicity profile. We evaluated the efficacy and toxicity of metronomic capecitabine (MC) in patients with advanced HCC. Patients and Methods: From May 2010, we enrolled pts with either metastatic or locally advanced diseases not candidate for ablative or locoregional treatment and have acceptable liver function. Patients received oral MC in dose of 1000 mg/m2 daily in a 21 days cycle without interruption till disease progression or toxicity. Results: The study cohort consisted of 22 patients with a median age of 63 years. The median number of cycles received was 3 cycles (range 1 - 9). From 19 patients were evaluable for response we had 3 partial responders, 10 stable diseases and disease progression in 6 patients. Median time to progression (TTP) was 2.2 months (95% CI 1.4 - 6.24) and median survival time (OS) was 4.8 months (95% CI 1.8 - 7.9). For 20 patients evaluable for safety: no grade III/IV hematological toxic effects were observed. Non-hematological toxic effects included grade III vomiting and diarrhea in one patient and grade III hand-foot syndrome in one patient. There was no treatment-related mortality. Conclusions: Based on the observed response rate, TTP and OS; MC has a modest antitumor efficacy in pts with advanced HCC. However, due to its low toxicity profile it deserves further attention as a convenient, outpatient-based chemotherapy regimen.
Targeting cancers in the gastrointestinal tract: role of capecitabine  [cached]
Muhammad Wasif Saif
OncoTargets and Therapy , 2009,
Abstract: Muhammad Wasif SaifYale Cancer Center, Yale University School of Medicine, New Haven, CT, USAAbstract: Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers. Keywords: 5-fluorouracil, capecitabine, chemotherapy, adjuvant, advanced, colon cancer, gastric cancer, hepatocellular cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, anal cancer
The Effect of Disease Site (Knee, Hip, Hand, Foot, Lower Back or Neck) on Employment Reduction Due to Osteoarthritis  [PDF]
Eric C. Sayre,Linda C. Li,Jacek A. Kopec,John M. Esdaile,Sherry Bar,Jolanda Cibere
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0010470
Abstract: Osteoarthritis (OA) has a significant impact on individuals' ability to work. Our goal was to investigate the effects of the site of OA (knee, hip, hand, foot, lower back or neck) on employment reduction due to OA (EROA).
Relationship between Self-Care and Hand Foot Syndrome Specific Quality of Life in Cancer Patients  [PDF]
Naoko Mikoshiba, Noriko Yamamoto-Mitani, Kazuki Sato, Yukari Yaju, Mitsunori Miyashita
Open Journal of Nursing (OJN) , 2016, DOI: 10.4236/ojn.2016.62011
Abstract: Purpose: The purpose of this study was to describe adherence to self-care for hand-foot syndrome (HFS) and the relationship between self-care and health-related quality of life (QOL). Methods: A cross-sectional study was conducted on 105 consecutive outpatients with HFS. To assess self-care for HFS and QOL, the participants were asked to complete self-care and HFS-14 (hand-foot syndrome specific QOL) questionnaires, respectively. Multiple regression models were used to identify the relationship between self-care and QOL. Results: Adherence to self-care for HFS was low, less than 50% for most of the items. Multivariate analysis revealed that poorer self-care (βs = -0.19; P = 0.03), depressive symptoms (βs = 0.43; P < 0.0001), and being employed (βs = 0.20; P = 0.04) were independent predictors of poorer QOL scores. Conclusions: We have identified a need for further research to develop effective programs of self-care in HFS.
Targeting cancers in the gastrointestinal tract: role of capecitabine
Muhammad Wasif Saif
OncoTargets and Therapy , 2009, DOI: http://dx.doi.org/10.2147/OTT.S3469
Abstract: rgeting cancers in the gastrointestinal tract: role of capecitabine Review (4598) Total Article Views Authors: Muhammad Wasif Saif Published Date March 2009 Volume 2009:2 Pages 29 - 41 DOI: http://dx.doi.org/10.2147/OTT.S3469 Muhammad Wasif Saif Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA Abstract: Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers.
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.